Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.
about
Hypertriglyceridaemia and risk of coronary artery disease.Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose AtorvastatinCOSMIC project: consensus on the objectives of the metabolic syndrome in clinic
P2860
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Current practice in identifyin ...... ith atherogenic dyslipidaemia.
@ast
Current practice in identifyin ...... ith atherogenic dyslipidaemia.
@en
type
label
Current practice in identifyin ...... ith atherogenic dyslipidaemia.
@ast
Current practice in identifyin ...... ith atherogenic dyslipidaemia.
@en
prefLabel
Current practice in identifyin ...... ith atherogenic dyslipidaemia.
@ast
Current practice in identifyin ...... ith atherogenic dyslipidaemia.
@en
P2093
P2860
P50
P356
P1476
Current practice in identifyin ...... ith atherogenic dyslipidaemia.
@en
P2093
Alberto Mello E Silva
Alberto Zambon
Carlos Aguiar
Eduardo Alegria
Francesco Cosentino
Jean Ferrières
Jesus Millan
José Luis Zamorano
Lale Tokgozoglu
Margus Viigimaa
P2860
P304
P356
10.1093/EURHEARTJ/SUW009
P433
P577
2016-04-01T00:00:00Z